How advances in immunology provide insight into improving vaccine efficacy

doi:10.1016/j.vaccine.2014.03.078

Vaccine

Volume 32, Issue 25, 23 May 2014, Pages 2948-2957

https://doi.org/10.1016/j.vaccine.2014.03.078 Get rights and content

Highlights

•
We discuss the importance of vaccines in preventing a number of infectious diseases.
•
We examine the general requirement for booster vaccination.
•
We describe how the duration of immunity may differ from the duration of protection.
•
We present potential mechanisms underlying the development of durable immunity.

Abstract

Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.

Section snippets

Introduction: Success of current vaccines

It is difficult to over-emphasize the role that vaccines have played in public health by controlling infectious disease, improving the quality of life and increasing life expectancy. For example, analysis of the impact of immunization with 7 of the 12 vaccines administered during routine childhood immunization in 2001 revealed that within a single US birth cohort, these vaccines prevent 33,000 deaths and 14 million cases of disease [1]. In addition to reducing morbidity and mortality, this

Duration of immunity depends on the characteristics of the vaccine or infection

Studies describing the duration of immunological memory following acute viral infection date back to the time of Panum, who in 1847, reported that the maintenance of long-term immunity against measles could be sustained for up to 65 years in the absence of re-exposure to the pathogen [10]. Studies by our group [11] previously showed that infection with measles virus results in stable serum antibody responses that are largely maintained above a protective threshold for life (95% confidence

Duration of T cell memory and immune correlates of cellular immunity

Many advances in the quantitative analysis and functional characterization of CD4⁺ and CD8⁺ T cell memory have occurred over the last two decades. The frequency of antigen-specific T cell responses can be measured by a variety of approaches including MHC Class I tetramers, peptide-induced intracellular cytokine staining, and IFNγ ELISPOT [28]. Moreover, with substantial advances in flow cytometry instrumentation and reagents, a large number of T cell functions and phenotypic markers can be

Role of adjuvants in determining the magnitude and duration of immunity

Adjuvants have been used extensively in clinical settings to enhance the efficacy of inactivated or recombinant vaccine antigens [43], [44], [45]. In general, adjuvants have been shown to increase the magnitude of vaccine-mediated immune responses, which may manifest as increased seroconversion rates, antigen dose sparing effects, or the ability to use fewer immunizations to achieve comparable levels of immunity [45]. However, there is also the expectation that advanced adjuvant systems,

All vaccines require boosters

One of the most common misconceptions in vaccinology is that inactivated vaccines and subunit vaccines are weaker immunogens and will require booster vaccination whereas live, attenuated vaccines are expected to elicit the same degree of durable protection as that achieved by natural infection. This does not appear to be the case since, with the possible exception of rubella, essentially all common childhood vaccines require booster vaccination regardless of whether they are non-replicating

The duration of immunity does not necessarily equate to the duration of protection

There are many instances in which natural infection with a particular virus will elicit essentially life-long immunity whereas infection with a closely related live attenuated vaccine strain of the same virus will not provide sufficient levels of immunity to confer long-term protection (Table 1). What is the difference between natural infection vs. vaccination that results in the necessity of booster immunization in order to achieve and maintain protective immunity? Most likely the differences

Lessons from vaccines that elicit immunity of differing duration

Vaccines have provided many success stories and even a requirement for a single booster vaccination is a small price to pay for durable immunity without necessitating severe or potentially life-threatening disease from natural infection. However, some vaccines are only partially effective even after multiple vaccinations (e.g., acellular pertussis) and development of better vaccination strategies that require fewer boosters is an important goal, especially in developing countries in which

Potential mechanisms underlying the development of durable humoral immune responses

One of the most intriguing questions regarding human vaccination is why certain vaccine antigens induce robust lifelong antibody responses, while protective immunity to other antigens fades with time. As discussed earlier, we found that humoral immunity to viruses tends to be long-lived, while immunity to non-repetitive protein antigens declines more quickly [11]. For example, long-term antibody responses to measles, mumps, and rubella demonstrated no significant decline in antibody when

Acknowledgments

This project was funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, R44 AI079898 (to MKS and IJA), R01 AI098723 (to MKS) and Oregon National Primate Research Center grant, 8P51 OD011092-53 (to MKS). OHSU, Dr. Slifka, and Dr. Amanna have a financial interest in Najít Technologies, Inc., a company that is developing new vaccines using a hydrogen peroxide-based inactivation approach. This potential individual and institutional conflict of interest has

References (95)

L. Deml et al.
Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses
Mol Immunol
(2005)
E. Traggiai et al.
Antigen dependent and independent mechanisms that sustain serum antibody levels
Vaccine
(2003)
A.L. Gregson et al.
Does antigenic overload exist? The role of multiple immunizations in infants
Immunol Allergy Clin North Am
(2003)
I.J. Amanna et al.
Impact of infection or vaccination on pre-existing serological memory
Hum Immunol
(2012)
J.M. Walker et al.
The immunostimulatory power of acute viral infection
Immunity
(2008)
J.D. Miller et al.
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines
Immunity
(2008)
T.P. Monath et al.
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections
Vaccine
(2002)
S.P. Buchbinder et al.
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Lancet
(2008)
R.L. Coffman et al.
Vaccine adjuvants: putting innate immunity to work
Immunity
(2010)
G. Aichinger et al.
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial
Vaccine
(2011)

T.P. Monath et al.

Yellow fever vaccine

D. Patel et al.

Yellow fever vaccination: is one dose always enough?

Travel Med Infect Dis

(2013)

M.P. Grobusch et al.

Yellow fever revaccination guidelines change—a decision too feverish?

Clin Microbiol Infect

(2013)

L.A. Jackson

(2013)

J.D. Cherry et al.

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis

Clin Vaccine Immunol

(2010)

P.L. Panum

Observations made during the epidemic of measles on the Faroe Islands in the year 1846

(1847)

I.J. Amanna et al.

Duration of humoral immunity to common viral and vaccine antigens

N Engl J Med

(2007)

M. Bonsignori et al.

HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection

J Immunol

(2009)

J.L. Perfettini et al.

Mechanisms of apoptosis induction by the HIV-1 envelope

Cell Death Differ

(2005)

T. Slocombe et al.

Plasma cell homeostasis: the effects of chronic antigen stimulation and inflammation

J Immunol

(2013)

H. Huang et al.

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

Proc Nat Acad Sci U S A

(2010)

D.R. Burton et al.

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

Science

(2012)

D. Sok et al.

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies

PLoS Pathog

(2013)

N.L. Bernasconi et al.

Maintenance of serological memory by polyclonal activation of human memory B cells

Science

(2002)

A. Radbruch et al.

Competence and competition: the challenge of becoming a long-lived plasma cell

Nat Rev Immunol

(2006)

I.J. Amanna et al.

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity

Immunol Rev

(2010)

S. Dhillon et al.

Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra)

Paediatr Drugs

(2008)

P.A. Offit et al.

Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant's immune system?

Pediatrics

(2002)

K.M. Posfay-Barbe et al.

How do physicians immunize their own children? Differences among pediatricians and nonpediatricians

Pediatrics

(2005)

Cited by (92)

Immunoprotection of FliBc chimeric fiber2 fusion proteins targeting dendritic cells against Fowl adenovirus serotype 4 infection
2024, Poultry Science
Hepatitis-hydropericardium syndrome (HHS) is a highly fatal disease in chickens caused by the highly pathogenic fowl adenovirus serotype 4 (FAdV-4), which has severe economic consequences. The fiber2 protein exhibits excellent potential as a candidate for a subunit vaccination against FAdV-4. Despite having a high safety profile, subunit vaccines have low immunogenicity due to their lack of infectivity, which leads to low levels of immune response. As a vaccine adjuvant, Salmonella flagellin possesses the potential to augment the immunological response to vaccinations. Additionally, a crucial strategy for enhancing vaccine efficacy is efficient presentation of immune antigens to dendritic cells (DC) for targeted vaccination. In this study, we designed FAdV-4-fiber2 protein, and a recombinant protein called FliBc-fiber2-SP which based on FAdV-4-fiber2 protein, was generated using the gene sequence FliBc, which retains only the conserved sequence at the amino and carboxyl termini of the flagellin B subunit, and a short peptide SPHLHTSSPWER (SP), which targets chicken bone marrow-derived DC. They were separately administered via intramuscular injection to 14-day-old specific pathogen-free (SPF) chickens, and their immunogenicity was compared. At 21 d postvaccination (dpv), it was found that the FliBc-fiber2-SP recombinant protein elicited significantly higher levels of IgG antibodies and conferred a vaccine protection rate of up to 100% compared to its counterpart fiber2 protein. These results suggest that the DC-targeted peptide fusion strategy for flagellin chimeric antigen construction can effectively enhance the immune protective efficacy of antigen proteins.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial
2023, Vaccine: X
The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity.
In this double-blind, placebo-controlled, phase I trial, we randomly assigned 135 healthy adults between 18 and 55 to receive vaccine strengths of 5 or 10 μg/dose or placebo (adjuvant only) in 0–14 or 0–21 schedules. This trial was conducted in a single center in a community setting. The safety outcomes in this study were reactogenicity, local and systemic adverse reactions, abnormal laboratory findings, and Medically Attended Adverse Events (MAAE). Immunogenicity outcomes include serum neutralizing antibody activity and specific IgG antibody levels.
The most frequent local adverse reaction was tenderness (28.9%), and the most frequent systemic adverse reaction was headache (9.6%). All adverse reactions were mild, occurred at a similar incidence in all six groups, and were resolved within a few days. In the 10-µg/dose vaccine group, the geometric mean ratio for neutralizing antibody titers at two weeks after the second injection compared to the placebo group was 9.03 (95% CI: 3.89–20.95) in the 0–14 schedule and 11.77 (95% CI: 2.77–49.94) in the 0–21 schedule. The corresponding figures for the 5-µg/dose group were 2.74 (1.2–6.28) and 5.2 (1.63–16.55). The highest seroconversion rate (four-fold increase) was related to the 10-µg/dose group (71% and 67% in the 0–14 and 0–21 schedules, respectively).
FAKHRAVAC® is safe and induces a strong humoral immune response to the SARS-CoV-2 virus at 10-µg/dose vaccine strength in adults aged 18–55. This vaccine strength was used for further assessment in the phase II trial.
Trial registration
This study is registered with https://www.irct.ir; IRCT20210206050259N1.
Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results
2022, Vaccine
Very limited data are available on the persistence of rubella antibodies in vertically HIV-infected individuals who were vaccinated early in life.
Prospective, cohort study on 4 groups of patients: 96 vertically HIV-1-infected individuals (v-HIV), 69 horizontally HIV-1-infected individuals (h-HIV), 93 healthy controls previously vaccinated for rubella (vac-CON) and 20 healthy controls with history of rubella disease (dis-CON). A blood sample was collected and rubella antibodies were analyzed by ELISA. Rubella antibodies above 10 IU/mL were considered protective. Individuals with seronegative results were offered an extra MMR vaccine dose and were tested at least 30 days afterwards.
Time since previous rubella vaccination was similar in v-HIV, h-HIV and vac-CON (16, 11 and 11 years; p = 0.428). v-HIV and h-HIV were also comparable regarding median CD4 T cells (613 and 614 cells/mm³; p = 0.599) and percentage on ART (93.8% and 98.6%; p = 0.135) at study entry. v-HIV had less individuals on virological suppression (63.5%) compared to 85.5% in h-HIV (p < 0.001). Rubella seropositivity and antibodies were significantly lower in v-HIV compared to h-HIV (32.3% vs 65.5%, 4.3 IU/mL vs 21.1 IU/mL; p < 0.001). Time interval between the last rubella vaccine dose and study entry was associated with an increase of rubella seronegativity, with a 7% higher chance of seronegativity for each one-year increase. After an extra MMR dose, 40 out of 48 (83.3%) seronegative individuals responded, with no significant difference among groups considering rubella seropositivity and antibody levels.
As vertically HIV-infected individuals reach adolescence and adulthood, assessment of vaccine antibodies can identify those who might benefit from an extra vaccine dose.
Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health
2022, Vaccine
Citation Excerpt :
To evaluate immunogenicity, we examined the antibody titers to the A(H1N1)pdm09 vaccine strain at T1 and T2 (Table 2). At T1, both vaccinated and unvaccinated groups had similar SPRs and GMTs (SPR: 63% vs 59%, p = 0.521; GMTs [95% CIs]: 41 [35 –48] vs 36 [26 –49], p = 0.480). At T2, SPR, SCR, GMT, and MFR from T1-T2 in the vaccinated group were all significantly higher than those in the unvaccinated group (SPR: 98% vs 65%, p < 0.0001; SCR: 77% vs 16%, p < 0.0001; GMTs [95% CIs]: 363 [322–410] vs 50 [36–70], p < 0.0001; MFR [95% CI]: 9.0 fold [7.6–10.5] vs 1.4 fold [1.1–1.9], p < 0.0001).
The objective of this study was to evaluate the effects of prior-infection and repeated vaccination on post-vaccination antibody titers.
A(H1N1)pdm09 strain was included in 2009 pandemic monovalent, 2010–2011, and 2011–2012 trivalent influenza vaccines (MIVpdm09, TIV10/11, TIV11/12) in Taiwan. During the 2011–2012 influenza season, we conducted a prospective sero-epidemiological cohort study among schoolchildren from grades 1 – 6 in the two elementary schools in Taipei with documented A(H1N1)pdm09 vaccination records since 2009. Serum samples were collected at pre-vaccination, 1-month, and 4-months post-vaccination (T1, T2, T3). Anti-A(H1N1)pdm09 hemagglutination inhibition titers (HI-Ab-titers) were examined. We also investigated the impact of four vaccination histories [(1) no previous vaccination (None), (2) vaccinated in 2009–2010 season (09v), (3) vaccinated in 2010–2011 season (10v), and (4) vaccinated consecutively in 2009–2010 and 2010–2011 seasons (09v + 10v)] and pre-vaccination HI-Ab levels on post-vaccination HI-Ab responses as well as adjusted vaccine effectiveness (aVE) against serologically-defined infection from T2 to T3.
TIV11/12 had zero serious adverse events reported. A(H1N1)pdm09 strain in TIV11/12 elicited seroprotective Ab-titers in 98% of children and showed promising protection (aVE: 70.3% [95% confidence interval (CI): 51.0–82.1%]). Previously unvaccinated but infected children had a 3.96 times higher T2 geometric mean titer (T2-GMT) of HI-Ab than those naïve to A(H1N1)pdm09 (GMT [95% CI]: 1039.7[585.3–1845.9] vs. 262.5[65.9–1045], p = 0.046). Previously vaccinated children with seroprotective T1-Ab-titers had a higher T2-GMT and a greater aVE than those with non-seroprotective T1-Ab-titers. Repeatedly vaccinated children had lower T2-GMT than those receiving primary doses of TIV11/12. However, after controlling prior infection and T1-Ab-titers, differences in T2-GMT among the four vaccination histories became insignificant (p = 0.16).
This study supports the implementation of annual mass-vaccination with A(H1N1)pdm09 in schoolchildren for three consecutive influenza seasons when vaccine and circulating strains were well matched, and found that prior infection and pre-vaccination HI-Ab levels positively impacted post-vaccination HI-Ab responses.
Getting to the (germinal) center of humoral immune responses to SARS-CoV-2
2022, Cell
In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy
2021, Acta Biomaterialia
Metastasis is the leading cause of death in cancer patients. Eliciting anti-tumor immune responses against lung metastasis is hindered by the immunosuppressive microenvironment. This study explored a biomimetic nanoformulation, comprising a nanovaccine (OP) that delivers tumor antigens and adjuvants spatially and temporally in a virus-like manner, and a pulmonary surfactant-biomimetic liposome with an immunomodulator, JQ1 (PS-JQ1). The findings of this study showed that intratracheal administration of OP+PS-JQ1 activated lung immune cells without concomitant excess inflammation, enhanced tumor antigen cross-presentation, generated a significantly high antigen-specific CD8⁺ T cell response, and reshaped the immunocellular composition in B16 melanoma tumor-bearing lung. OP+PS-JQ1 nanoformulation exhibited a striking immunotherapeutic efficacy, induced local and systemic tumor suppression, improved survival of mice, initiated immune memory that prevents recurrence of secondary tumors. This stable and nontoxic nanoformulation provides a simple, flexible, and robust strategy for augmenting anti-tumor immunity for metastatic cancer.
Egg glue proteins are produced by female insects, which can make the eggs firmly attached to the oviposition sites, not affected by wind and rain. However, genes encoding insect egg glue proteins have not yet been reported, and the molecular mechanism underpinning their adhesion is still unknown. Our study makes a significant contribution to the literature as it identifies the sequence, structure, adhesive property, and mechanism of silkworm egg glue protein. Furthermore, it outlines key insights into the structure-function relationships associated with egg glue proteins. We believe that this paper will be of interest to the readership of your journal as it identifies the first complete sequence of insect egg glue proteins, thereby highlighting their potentials future applications in both the biomedical and technical fields.

View all citing articles on Scopus

View full text

ReviewHow advances in immunology provide insight into improving vaccine efficacy

Highlights

Abstract

Section snippets

Introduction: Success of current vaccines

Duration of immunity depends on the characteristics of the vaccine or infection

Duration of T cell memory and immune correlates of cellular immunity

Role of adjuvants in determining the magnitude and duration of immunity

All vaccines require boosters

The duration of immunity does not necessarily equate to the duration of protection

Lessons from vaccines that elicit immunity of differing duration

Potential mechanisms underlying the development of durable humoral immune responses

Acknowledgments

Mol Immunol

Vaccine

Immunol Allergy Clin North Am

Hum Immunol

Immunity

Immunity

Vaccine

Lancet

Immunity

Vaccine

Vaccine

Vaccine

Vaccine

Travel Med Infect Dis

Clin Microbiol Infect

Vaccine

Vaccine

Lancet Infect Dis

Int J Pharm

Curr Opin Virol

Vaccine

Immunity

Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001

Arch Pediatr Adolesc Med

Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States

JAMA

Notifiable diseases and mortality tables

MMWR: Morb Mortal Wkly Rep

Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease

N Engl J Med

Public health, the pertussis paradox

Science

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010

JAMA

Number and order of whole cell pertussis vaccines in infancy and disease protection

JAMA

Waning immunity to pertussis following 5 doses of DTaP

Pediatrics

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis

Clin Vaccine Immunol

Observations made during the epidemic of measles on the Faroe Islands in the year 1846

Duration of humoral immunity to common viral and vaccine antigens

N Engl J Med

HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection

J Immunol

Mechanisms of apoptosis induction by the HIV-1 envelope

Cell Death Differ

Plasma cell homeostasis: the effects of chronic antigen stimulation and inflammation

J Immunol

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

Proc Nat Acad Sci U S A

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

Science

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies

PLoS Pathog

Maintenance of serological memory by polyclonal activation of human memory B cells

Science

Competence and competition: the challenge of becoming a long-lived plasma cell

Nat Rev Immunol

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity

Immunol Rev

Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra)

Paediatr Drugs

Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant's immune system?

Pediatrics

How do physicians immunize their own children? Differences among pediatricians and nonpediatricians

Pediatrics

Review
How advances in immunology provide insight into improving vaccine efficacy